Therapeutic application of mesenchymal stromal cells in murine models of inflammatory bowel disease
Elena Gonzalez-Rey1, Mario Delgado
1Institute of Parasitology and Biomedicine "Lopez-Neyra", CSIC, Avenida del Conocimiento s/n, 18016, Granada, Spain.
Abstract:
Mesenchymal stromal cells (MSCs) are currently under investigation for the treatment of inflammatory bowel disease (IBD), including Crohn's disease. The models of colitis induced by intrarectal infusion of 2,4,6-trinitrobenzene sulfonic acid (TNBS) or by oral administration of dextran sulfate sodium (DSS) in susceptible mouse strains have been commonly used as preclinical tools to demonstrate the efficiency of treatments with MSCs isolated from various sources. Both models are being and will be critical to improve MSC-based therapies in human IBD by assaying new pathways, therapeutic regimes and tissue targeting strategies. Here, we describe our experiences in the treatment of acute and chronic TNBS- and DSS-induced colitis with MSCs.
Insights
Mesenchymal stromal cells (MSCs) show promise for treating inflammatory bowel disease (IBD). This study details experiences using MSCs to treat mouse models of colitis, aiding the development of future IBD therapies.
Area of Science:
- Immunology
- Regenerative Medicine
- Gastroenterology
Background:
- Mesenchymal stromal cells (MSCs) are being investigated for inflammatory bowel disease (IBD) treatment.
- Preclinical models of colitis are essential for evaluating MSC-based therapies.
Purpose of the Study:
- To describe experiences treating acute and chronic colitis models with MSCs.
- To highlight the utility of TNBS and DSS colitis models for advancing MSC therapies in human IBD.
Main Methods:
- Utilized 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis model.
- Utilized dextran sulfate sodium (DSS)-induced colitis model.
- Administered Mesenchymal stromal cells (MSCs) to treat induced colitis in mice.
Main Results:
- MSCs were tested in both acute and chronic models of TNBS- and DSS-induced colitis.
- The study details the application of MSCs in established preclinical models of IBD.
- Experiences with MSC treatment in these models are documented.
Conclusions:
- TNBS and DSS colitis models are critical for improving MSC-based therapies for human IBD.
- Further research using these models will refine therapeutic regimes and targeting strategies for MSCs.
- The study contributes to the understanding of MSC efficacy in IBD preclinical models.
Related Concept Videos
01:19Mesenchymal Stem Cells
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents